IDV vehicle

36E79724D0018

AWARD TO XLCARE PHARMACEUTICALS FOR METHOCARBAMOL TABLETS FOR THE BASE YEAR WITH FOUR ONE-YEAR OPTIONS.

Research the contractorView USAspending sourceSave to my pursuit research

Award details

Obligations, current value and potential value describe different measures; they are never added together.

FieldReported value
AgencyDepartment of Veterans Affairs
OfficeNAC PHARMACEUTICALS (36E797)
NAICS325412 — Pharmaceutical Preparation Manufacturing
PSC6505 — Drugs and Biologicals
Parent award / vehicleNot reported
Set-asideNO SET ASIDE USED.
Pricing typeFIRM FIXED PRICE
Obligations$0
Current contract valueNot reported
Potential contract value / ceiling$11.6M
Start dateMar 23, 2024
Current end dateNot available
Potential end dateNot available
Latest award activityAug 31, 2026
Source loadedSep 26, 2026

Funding and modification history

Showing the latest 5 of 5 loaded transactions. Negative values are deobligations.

DateModificationObligation changeDescription
Aug 31, 2026P00004$0IMPLEMENTING EO 14398 DEI DISCRIMINATION
Feb 3, 2026P00003$0EXERCISE OPTION YEAR 2 FOR METHOCARBAMOL TABLETS. PERIOD OF PERFORMANCE 3/23/2026 - 3/22/2027.
Mar 11, 2025P00002$0EXERCISE OPTION YEAR 1 FOR METHOCARBAMOL TABLETS. PERIOD OF PERFORMANCE 3/23/2025 - 3/22/2026.
Feb 15, 2024P00001$0UPDATE TO COST RECOVERY FEE (CRF) AND SUBMISSION OF QUARTERLY SALES REPORTS
Jan 24, 20240$0AWARD TO XLCARE PHARMACEUTICALS FOR METHOCARBAMOL TABLETS FOR THE BASE YEAR WITH FOUR ONE-YEAR OPTIONS.

Buyer contacts from matching notices

Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.

ContactRolePublished contact methodsEvidenceSource date
Anthony DiCrescenzoContract SpecialistAnthony.DiCrescenzo@va.govSourceDec 6, 2023
Anthony Di CrescenzoContract Specialistanthony.dicrescenzo@va.gov
708-786-4984
SourceDec 5, 2023

Research next steps

  1. Check the stated set-aside against the solicitation and current certifications.
  2. Review the award scope and buyer evidence before making a bid/no-bid decision.